WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005037835) NOVEL THIOXANTHINE DERIVATIVES FOR USE AS INHIBITORS OF MPO
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/037835    International Application No.:    PCT/SE2004/001477
Publication Date: 28.04.2005 International Filing Date: 14.10.2004
IPC:
C07D 473/22 (2006.01)
Applicants: ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE) (For All Designated States Except US).
KETTLE, Anthony [NZ/NZ]; (NZ) (For US Only).
TIDÉN, Anna-Karin [SE/SE]; (SE) (For US Only)
Inventors: KETTLE, Anthony; (NZ).
TIDÉN, Anna-Karin; (SE)
Agent: ASTRAZENECA; Global Intellectual Property, S-151 85 Södertälje (SE)
Priority Data:
0302756-2 17.10.2003 SE
Title (EN) NOVEL THIOXANTHINE DERIVATIVES FOR USE AS INHIBITORS OF MPO
(FR) NOUVEAUX DERIVES DE THIOXANTHINE UTILES COMME INHIBITEURS DE LA MPO
Abstract: front page image
(EN)There are disclosed novel compounds of formula (Ia) or (Ib) wherein R1, R2, R3, R4, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.
(FR)L'invention concerne des nouveaux composés de formule (Ia) ou (Ib), dans laquelle R1, R2, R3, R4, X et Y sont tels que définis dans la description, ainsi que des sels pharmaceutiquement acceptables desdits composés. L'invention concerne également des procédés de préparation de ces composés, des compositions les contenant et leur utilisation à des fins thérapeutiques. Ces composés sont des inhibiteurs de l'enzyme MPO. Par conséquent, ils sont particulièrement utiles dans le traitement ou la prévention de troubles neuro-inflammatoires.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)